Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease  by Schrier, Robert W. et al.
Kidney International, Vol. 63 (2003), pp. 678–685
Epidemiological study of kidney survival in autosomal
dominant polycystic kidney disease
ROBERT W. SCHRIER, KIMBERLY K. MCFANN, and ANN M. JOHNSON
Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA
Epidemiological study of kidney survival in autosomal domi- hemophilia, Down’s syndrome, and Huntington’s disease
nant polycystic kidney disease. combined [3], and accounts for 4.4% of end-stage renal
Background. It is unknown whether the substantial increase disease (ESRD) in the United States [4]. Despite thein research, identification of risk factors for renal progression,
importance of the disease, decades passed with very littlegreater antihypertensive armamentarium including inhibitors
ADPKD research performed. In the last 15 years, how-of the renin-angiotensin-aldosterone system (RAAS) and en-
hanced educational information have impacted the progression ever, a dramatic increase in ADPKD research has oc-
of autosomal dominant polycystic kidney disease (ADPKD) curred. In that regard, several factors have been identi-
renal disease. fied that predict a more rapid deterioration of renalMethods. An epidemiological study involving 513 ADPKD
function including age, male gender, hematuria, protein-subjects was performed. The hypothesis tested was that over
uria, type 1 gene mutations on chromosome 16 as com-two separate periods, 1985 to 1992 versus 1992 to 2001, a
significant slowing of renal function loss in ADPKD patients pared to type 2 mutations on chromosome 4, renal cyst
would be demonstrated in association with improved blood volume, hypertension, increased left ventricular mass in-
pressure (BP) control and inhibition of the RAAS as instituted dex (LVMI) [5] and African American race [6]. It is notby their primary care physicians.
known, however, whether these discoveries have alteredResults. ADPKD males and females in the later cohort (1992
the natural history of renal progression in ADPKD pa-to 2001) had longer mean and median survival times to ESRD
than males and females in the earlier cohort (1985 to 1992). tients.
Analysis revealed that both males and females in the later Of the risk factors for renal disease progression in
cohort had significantly lower diastolic blood pressure (DBP) ADPKD, the most readily treatable is hypertension. Theand mean arterial pressure (MAP) values than males and fe-
pathogenesis of the hypertension has been shown to in-males in the earlier cohort. ADPKD male and female patients
volve the renin-angiotensin-aldosterone system (RAAS)in the later cohort used significantly more angiotensin con-
verting enzyme inhibitors (ACEIs) than ADPKD male and [7–9], and angiotensin-converting enzyme inhibitors
female patients in the earlier cohort. (ACEIs) and angiotensin receptor blockers (ARBs) in
Conclusions. These results demonstrate a significant slowing recent years have become available to lower blood pres-of ADPKD renal progression in both male and female patients
sure (BP). While inhibition of the RAAS in ADPKDthat was associated with a significantly lower MAP and in-
patients has been shown to exert a significantly greatercreased use of ACEIs in the later cohort (1992 to 2001) as
compared to the early cohort (1985-1992). antihypertensive effect than diuretics [10] and reversal
of LVMI than the use of calcium channel blockers (CCBs)
[11], no difference in the progression of renal disease
Autosomal dominant polycystic kidney disease was demonstrated. BP control in ADPKD patients to a
(ADPKD) is the most frequent life-threatening heredi- goal of less than 120/80 mm Hg over a seven year period
tary disease, occurring in 1 in 400 to 1000 people of was more effective in reversing LVMI than standard
European descent [1, 2]. ADPKD is more frequent than (135–140/85–90 mm Hg) BP control, but no difference
sickle cell anemia, cystic fibrosis, muscular dystrophy, in renal progression was demonstrated [11]. Moreover,
no difference in renal progression was shown in a ran-
domized study comparing ACEIs versus -adrenergic
Key words: autosomal dominant polycystic kidney disease, hyperten-
blockade (abstract; Watson et al, J Am Soc Nephrol 10:sion, kidney survival, end-stage renal disease, renin-angiotensin-aldo-
sterone system. 415A, 1999); both of these agents, however, suppress the
RAAS. In a retrospective longitudinal study it was shownReceived for publication May 16, 2002
that ADPKD patients treated with diuretics withoutand in revised form August 28, 2002
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[10]. Moreover, BP control to less than 140/90 mm Hg At each study visit subjects had blood drawn to deter-
mine routine serum chemistries. Blood was drawn alsoin ADPKD patients by primary care physicians has in-
for linkage analysis for those subjects who had severalcreased from 38% to 64% over the last 15-year period
family members for study. Linkage analysis for PKD-1[12], an improvement not documented to have occurred
and 2 was performed in the laboratory of Dr. Kimberling,in the treatment of essential hypertension [13].
(Boystown, Omaha, NE, USA) using established mark-With this background the present ADPKD epidemio-
ers for the PKD-1 and PKD-2 genes [14]. Of the 513logical study was undertaken to examine whether the
subjects, 148 were determined to be from 59 PKD-1substantial increase in research, identification of risk fac-
families; linkage analysis was not completed on the re-tors for renal progression, greater antihypertensive ar-
maining 365 subjects due to insufficient family data. Pro-mamentarium including inhibition of the RAAS and en-
teinuria was determined by two 24-hour urine collectionshanced educational information for ADPKD patients
obtained during the patients’ stay in the GCRC. Urinaryand their primary care physicians have impacted the
protein concentrations were determined by the Coomas-progression of ADPKD renal disease. Our hypothesis
sie blue dye-binding method. The mean of the two collec-tested whether over two separate periods, 1985 to 1992
tions was used to assess each individual’s level of protein-versus 1992 to 2001, a significant slowing of renal function
uria (mg/24 h). Mail-in questionnaires, phone calls, andloss could be demonstrated in association with improved
follow-up visits to the GCRC were used to obtain infor-BP control and inhibition of the RAAS in ADPKD
mation on patients’ renal survival status. ESRD was de-patients treated by their primary care physicians.
fined as starting dialysis treatment or receiving a renal
transplant.
METHODS
Statistical analysesFrom June 1985 to May 2001, 668 adult subjects with
The 513 ADPKD subjects were examined in two co-ADPKD participated in a longitudinal study of the natu-
horts: subjects examined between June 1985 and Mayral history of ADPKD at the University of Colorado
1992 and subjects examined between June 1992 and MayHealth Sciences Center. All subjects provided written
2001. Due to the known differences between male andinformed consent. Of the 668 subjects 513 met the inclu-
female ADPKD patients, all analyses were performedsion criteria for analysis: (1) Subjects had to have at
separately for males and females. A cohort effect wasleast one full examination at the University of Colorado
explored using independent samples t tests. Time fromGeneral Clinical Research Center (GCRC), (2) Subjects
birth to ESRD was computed by using the Kaplan-Meierhad to be over the age of 18 and under age 60 before
method. Survival analysis was performed to test the hy-their first visit to the GCRC, and (3) subjects could not
pothesis that subjects examined in the later (1992 tobe in ESRD at the time of the initial visit. Additionally,
2001) cohort had better renal survival time to ESRD21 subjects from three known PKD-2 families were ex-
than subjects in the earlier cohort. Multiple linear regres-cluded. None of the patients included in the study were
sion and multivariate logistic regression were performedinvolved in any interventional studies. The 513 subjects
to determine if mean arterial pressure (MAP) and renalwere cared for by their primary care physicians. Of the
volume were independently predictive of ESRD. Inde-513 subjects, 145 reported that they had seen a nephrolo-
pendent samples t tests were used to test for a cohortgist. At the study visit in the GCRC, participants had a
effect among hypertensive ADPKD subjects. Chi squarehistory and physical examination, and renal ultrasound
tests of independence were used to test if the types ofwas performed. Blood pressures were measured by
antihypertensive agents in the two groups were different.trained nurses of the GCRC using a Dinamap apparatus
Survival analysis was performed to test the hypotheses(Critikon Inc., Tampa, FL, USA). Hypertension was de-
that hypertensive ADPKD subjects examined in the laterfined as blood pressure 140/90 mm Hg or being on
cohort had better survival time to ESRD than hyperten-antihypertensive medication. Renal ultrasound examina-
sive ADPKD subjects in the earlier cohort.tions were performed in the Radiology Department of
the University of Colorado Health Sciences Center. Re-
nal volume was defined as the mean of both kidneys and RESULTS
was calculated using a standard formula for a modified The epidemiological study was performed on 513 sub-
ellipsoid for each kidney as follows: jects, 177 males and 336 females from 300 families, to
explore kidney survival in two cohorts. Of the 300 fami-
lies represented, 51 families in the early cohort and 61Renal volume 
4
3
  Anteroposterior diameter4 in the later cohort had more than one family member






2 Independent samples t tests revealed that the two co-
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Table 1. Comparison of characteristics of ADPKD males in two cohorts at the initial study visit
June 1985–May 1992 June 1992–May 2001
N  97 N  80
Mean SD Mean SD P
Age years 38 10 36 11 NS
BMI kg/m2 26.3 4.3 26.8 4.5 NS
SBP mm Hg 136 13 133 12 NS
DBP mm Hg 92 10 82 9 0.0001
MAP mm Hg 106 11 99 9 0.0001
Urinary protein excretion mg/24 h 409 612 272 540 NS
Renal volume cm3 826 584 834 839 NS
Serum creatinine mg/dL 2.0 1.4 1.6 1.1 NS
Hematuria % 45.3 26.3 0.0093
Table 2. Comparison of characteristics of ADPKD females in two cohorts at the initial study visit
June 1985–May 1992 June 1992–May 2001
N  158 N  178
Mean SD Mean SD P
Age years 37 10 39 11 NS
BMI kg/m2 24.0 4.4 26.9 7.1 0.0001
SBP mm Hg 125 12 127 14 NS
DBP mm Hg 84 9 80 9 0.0001
MAP mm Hg 98 10 95 10 0.0444
Urinary protein excretion mg/24 h 205 292 231 404 NS
Renal volume cm3 576 537 575 396 NS
Serum creatinine mg/dL 1.4 1.1 1.4 1.1 NS
Hematuria % 34.4 34.3 NS
Pregnancies 2.3 2.0 2.3 1.9 NS
horts were equivalent with respect to age at entry into
the study, body mass index, renal volume, urinary protein
excretion, and kidney function for males (Table 1) and
females (Table 2). There was no difference in the number
of pregnancies among females in the two cohorts (Table
2). There was a significant difference between the two
cohorts in diastolic blood pressure (DBP) and MAP for
males (Table 1) and females (Table 2). Additionally, a
higher percentage of patients in the later cohort reported
that they had seen a nephrologist than patients in the
early cohort (35.3 vs. 21.2%, P  0.0004).
Fig. 1. Survival time to ESRD for 97 male ADPKD subjects examinedSurvival analysis using the log-rank statistic revealed between June 1985 and May 1992 (dashed line; median 53 years) versus
a significant difference between survival curves for both 80 male ADPKD subjects examined between June 1992 and May 2001
(solid line; median 63 years; P  0.193).males and females in the later versus earlier cohorts.
Males in the later cohort had significantly longer mean
and median survival times to ESRD than males in the
earlier cohort. Males in the later cohort had a mean sion or were on antihypertensive medications at the time
survival time of 57.8 years and a median survival time of their first examination, 69.4% in the earlier cohort
of 63 years to ESRD compared to a mean of 51.3 years and 65.5% in the later cohort (PNS). The hypertensive
and a median of 53 years for the earlier cohort (Fig. 1). subjects in the two cohorts were then compared. Inde-
Females in the later cohort had a significantly longer pendent samples t tests revealed that for males, the two
mean survival time of 58.9 years and a median survival hypertensive cohorts were equivalent at entry into the
time of 61.0 years to ESRD compared to a mean of 55.8 study with respect to age, body mass index (BMI, kg/m2),
years and a median of 57 years for the earlier cohort renal volume, urinary protein excretion, and kidney
(Fig. 2). function, but differed significantly regarding DBP and
MAP (Table 3). Hypertensive males in the later cohortOf the 513 subjects, 346 had a diagnosis of hyperten-
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renal volume (P 0.0001) were both strong independent
predictors of the occurrence of ESRD. Males entering
ESRD had a mean MAP of 109  10 mm Hg and mean
renal volume of 1333  581 cm3 compared to a mean
MAP of 101  10 mm Hg and renal volume of 659 
675 cm3 for those not entering ESRD (P 0.0001 and
P  0.0001, respectively). Likewise, logistic regression
performed for female ADPKD subjects indicated that
MAP (P  0.0223) and renal volume (P  0.0001) were
both strong independent predictors of the occurrence of
ESRD. Females entering ESRD had a mean MAP of 102
11 mm Hg and mean renal volume of 1052  703 cm3Fig. 2. Survival time to ESRD for 158 female ADPKD subjects exam-
ined between June 1985 and May 1992 (dashed line; median 57 years) compared to a mean MAP of 95  9 mm Hg and renal
versus 178 female ADPKD subjects examined between June 1992 and volume of 488  346 cm3 for those not entering ESRD
May 2001 (solid line; median 61 years; P  0.0258).
(both P  0.0001). Logistic regression revealed that
ADPKD patients with a diagnosis of hypertension were
4.7 times more likely to enter ESRD than those without
a diagnosis of hypertension. Male subjects with a meanhad lower DBP and MAP than males in the earlier co-
hort. Chi square tests of independence demonstrated MAP greater than 93 mm Hg were 10.0 times more likely
to enter ESRD than male subjects with a MAP less thanthat the later cohort used more ACEIs and CCBs, while
the earlier cohort used more diuretics and -adrenergic or equal to 93 mm Hg (P  0.0294). Male subjects with
renal volumes greater than 1000 cm3 were 6.8 times moreblocking agents (Table 3). The earlier cohort was also
more likely to report at least one occurrence of gross likely to enter ESRD than male subjects with renal vol-
umes smaller than or equal to 1000 cm3 (P  0.0001).hematuria (Table 3).
Renal survival analysis comparing hypertensive males Female subjects with a MAP greater than 93 mm Hg
were 2.4 times more likely to enter ESRD than femalein the two cohorts demonstrated a significant difference
between the survival curves of the two cohorts (Fig. 3). subjects with a MAP less than or equal to 93 mm Hg
(P 0.0250). Female subjects with renal volumes greaterMales in the later cohort had a mean survival time of
57.6 years and a median survival time of 63 years to than 1000 cm3 were 5.1 times more likely to enter ESRD
than female subjects with renal volumes smaller than orESRD compared to a mean of 51.1 years and a median
of 53 years for the earlier cohort. equal to 1000 cm3 (P  0.0001).
There was no significant difference between hyperten-Independent samples t tests revealed that for females
the two hypertensive cohorts were equivalent at entry sive male ADPKD subjects in the earlier and later co-
horts on the mean number of antihypertensive medica-into the study with respect to age, renal volume, urinary
protein excretion, and kidney function, but significantly tions used (1.2  1.1 vs. 1.2  0.9, P  NS) or age of
diagnosis of hypertension (32.7  9.3 vs. 31.6  10.2different regarding BMI, DBP, and MAP (Table 4). Fe-
males in the later cohort had slightly higher BMI but years, PNS). Likewise, there was no significant differ-
ence between hypertensive female ADPKD subjects inlower DBP and MAP than females in the earlier cohort.
There was no significant difference in the number of the earlier and later cohorts on the mean number of
antihypertensive medications used (0.99  0.9 vs. 1.2 pregnancies between hypertensive females in the early
and later cohorts (2.6  2.1 vs. 2.5  1.9, P  NS). Chi 0.8, P NS) or age of diagnosis of hypertension (33.8 
9.6 vs. 34.0  10.3 years, P  NS). The frequency distri-square tests of independence demonstrated that the later
cohort used more ACEIs and CCBs, while the earlier butions of the number of antihypertensive medications
used by hypertensive ADPKD subjects in each cohortcohort used more -adrenergic blocking agents (Table
4). The percentage occurrence of hematuria did not sig- are presented in Table 5. Although there was no differ-
ence in the mean number of antihypertensive medica-nificantly differ between the two groups (Table 4).
Survival analysis comparing hypertensive females in tions used in the two cohorts, a higher percentage of
hypertensive ADPKD subjects in the earlier cohort werethe two cohorts demonstrated a significant difference
between the survival curves of the two cohorts (Fig. 4). not treated for their hypertension than in the later cohort
(P  0.0050; Table 5).Females in the later cohort had a mean survival time of
57.7 years and a median survival time of 60 years to Of the 513 ADPKD subjects, 167 did not have a diag-
nosis of hypertension upon entry into the study. NoneESRD compared to a mean of 54.8 years and a median
of 54 years for the earlier cohort. of the normotensive ADPKD males in either cohort
entered ESRD. Only six normotensive ADPKD femalesLogistic regression performed separately for male
ADPKD subjects indicated that MAP (P  0.0019) and entered ESRD, three in each cohort (P  NS). There
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Table 3. Comparison of characteristics of hypertensive ADPKD males in two cohorts at the initial study visit
June 1985–May 1992 June 1992–May 2001
N  81 N  61
Mean SD Mean SD P
Age years 40 9 38 10 NS
BMI kg/m2 26.5 4.3 27.5 4.3 NS
SBP mm Hg 138 13 135 12 NS
DBP mm Hg 94 9 85 9 0.0001
MAP mm Hg 109 10 102 9 0.0001
Urinary protein excretion mg/24 h 474 652 305 612 NS
Renal volume cm3 935 587 944 902 NS
Serum creatinine mg/dL 2.2 1.4 1.8 1.2 NS
N of antihypertensive medications 1.2 1.1 1.2 0.94 NS
ACEIs % 16.1 54.1 0.0001
CCBs % 9.9 23.0 0.0331
Diuretics % 42.2 13.1 0.0003
Sympathetic blocking agents (SBAs) % 40.7 23.0 0.0033
	-Blockers % 13.6 8.2 NS
-Blockers % 34.6 16.4 0.0155
Hematuria % 48.1 27.9 0.0151
the identification of the gene mutations for type 1 ADPKD
(chromosome 16) [15], type 2 ADPKD (chromosome 4)
[16] and more recently autosomal recessive PKD (chro-
mosome 6) [17]. The further identification of the ADPKD
gene protein products, polycystin-1 and polycystin-2, in-
cluding progress in understanding their functions and
interrelationships, have been exciting developments in
the field [18]. At the same time, numerous clinical studies
have identified the natural history of ADPKD including
the renal and extra-renal complications such as liver cysts
[19], berry aneurysms [20] and cardiac valvular defects
Fig. 3. Survival time to ESRD for 81 hypertensive male ADPKD [21–23]. Several risk factors for the progression of the
subjects examined between June 1985 and May 1992 (dashed line; functional renal disease also have been identified includ-
median 53 years) versus 61 hypertensive male ADPKD subjects exam-
ing gender, race, age, renal volume, proteinuria, hematu-ined between June 1992 and May 2001 (solid line; median 63 years;
P  0.0220). ria, hypertension, and LVMI [5, 6]. Among these risk
factors the most readily treatable factor is the hyper-
tension associated with ADPKD. The hypertension in
ADPKD patients occurs at a mean age of 30 years [24]was no significant difference between the two cohorts in
renal survival for either normotensive males or normo- and is associated with a substantial incidence of left ven-
tensive females (P  NS). tricular hypertrophy (LVH) [25]. Since cardiovascular
Multiple linear regression performed using data from events are the most common cause of death in ADPKD
all eligible subjects at the initial study visit revealed that patients [26], the occurrence of hypertension and LVH
age, (P  0.0001), renal volume (P  0.0001), urinary are extremely important cardiovascular risk factors for
protein excretion (P 0.0001), and gender (P 0.0296) ADPKD patients. It has been suggested that the pres-
were independently related to glomerular filtration rate ence of hypertension and the size of the cystic kidneys
(GFR) at the time of the visit. Multivariate logistic re- are determinants of the progression of the renal func-
gression performed using all subjects confirmed that age tional loss [5, 7, 9]. In the present study there was a
(P  0.0001), renal volume (P  0.0001), MAP (P  highly significant correlation between hypertension and
0.0026), and urinary protein excretion (P  0.0051), but renal volumes with the progression to ESRD in both
not gender (P  NS), were independent predictors of male and female patients with ADPKD. Logistic regres-
progression to ESRD.
sion analysis demonstrated that ADPKD male patients
with a MAP greater than 93 mm Hg (
120/80 mm Hg)
DISCUSSION were 10.0 times more likely to enter ESRD than those
patients with a MAP less than 93 mm Hg. A similarIn recent years the accelerated polycystic kidney dis-
ease (PKD) research has yielded dramatic results with comparison for female ADPKD patients demonstrated
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Table 4. Comparison of characteristics of hypertensive ADPKD females in two cohorts at the initial study visit
1985–May 1992 June 1992–May 2001
N  96 N  108
Mean SD Mean SD P
Age years 40 10 42 11 NS
BMI kg/m2 24.7 4.8 27.9 7.0 0.0004
SBP mm Hg 130 12 131 14 NS
DBP mm Hg 87 9 82 9 0.0001
MAP mm Hg 101 9 99 10 0.0384
Urinary protein excretion mg/24 h 267 360 276 420 NS
Renal volume cm3 703 631 697 419 NS
Serum creatinine mg/dL 1.7 1.3 1.6 1.3 NS
N of antihypertensive medications 1.0 0.90 1.2 0.81 NS
ACEIs % 13.5 48.2 0.0001
CCBs % 6.3 15.7 0.0345
Diuretics % 34.4 24.1 NS
Sympathetic blocking agents (SBAs) % 40.6 24.1 0.0113
	-Blockers % 6.3 5.6 NS
-Blockers % 34.4 19.4 0.0158
Hematuria % 46.8 41.7 NS
Table 5. Frequency distribution of the number of antihypertensive
medications used in the two study periods by hypertensive
ADPKD subjects
Number of
antihypertensive June 1985– June 1992–
medications used May 1992 May 2001 Total
0 63 37 100
1 51 78 129
2 50 43 93
3 12 10 22
4 1 1 2
Total 177 169 346
Fig. 4. Survival time to ESRD for 96 hypertensive female ADPKD
subjects examined between June 1985 and May 1992 (dashed line;
median 54 years) versus 108 hypertensive female ADPKD subjects
examined between June 1992 and May 2001 (dashed line; median 60 to have a significant increase in the use of ACEIs in the
years; P  0.0177). later versus earlier cohort (54.1 vs. 16.1%, P  0.0001
for males; 48.2 vs. 13.5% for females, P  0.0001). This
was associated with a significant decrease in the use of
diuretics and -adrenergic blocking agents. There wasthat those patients with a MAP greater than 93 mm Hg
also a modest increase in the use of CCBs for bothwere 2.4 times more likely to enter ESRD than those
hypertensive males and females with ADPKD.patients with MAP of 93 mm Hg or less. Moreover, renal
While the ability to slow or prevent renal cyst enlarge-volumes greater than 1000 cm3 for ADPKD male and
ment, as a means of slowing progression of the renalfemale patients were 6.8 and 5.1 times more likely to
disease in ADPKD, will no doubt need further research,enter ESRD, respectively.
the capacity to more aggressively control BP and inhibitAlthough the RAAS has been shown to be activated in
the RAAS are currently available. The hypothesis testedADPKD patients [8] and angiotensin is a known growth
in the present investigation is whether the clinical re-factor and a stimulator of transforming growth factor-
search implicating hypertension including activation of(TGF-) [27–32], to date no prospective randomized
the RAAS has led to an alteration in the care of theinterventional trial has been shown to alter the rate of
ADPKD patients in recent years and, if so, has thisrenal cyst growth by blocking the RAAS. The results of
alteration in care exacted an effect on the rate of progres-a retrospective longitudinal study, however, suggested
sion of the renal disease. The later cohort (1992 to 2001)that ACEIs may alter progression of ADPKD renal dis-
exhibited a significantly lower MAP and an increasedease compared to treatment with diuretics [10].
use of ACEIs compared to the earlier cohort (1985 toIn recent years ACEIs have been used more fre-
1992). In recent years ACEIs and CCBs have becomequently to treat essential hypertension. In the present
study both hypertensive males and females were shown the most commonly used antihypertensive medications
Schrier et al: Kidney survival in PKD684
of End-Stage Renal Disease in the United States. Bethesda, Nationalfor treating essential hypertension, with 38 and 33% of
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